Nordic Nanovector ASA: Mandatory notification of trade - primary insiders

Reference is made to the stock exchange notice issued by Nordic Nanovector ASA (the "Company") on 8 December 2016 regarding the management's share purchases in the Company. After the notice was published, the members of management have made the following transactions:

On 8 December 2016, Luigi Costa, CEO of Nordic Nanovector ASA purchased 5,929 shares in Nordic Nanovector ASA at an average price of NOK 114.00 per share. Following this transaction, Luigi Costa own 79,115 shares in Nordic Nanovector ASA and holds 1,088,106 options in the company.

On 8 December 2016, Tone Kvåle, CFO of Nordic Nanovector ASA purchased 1,754 shares in Nordic Nanovector ASA at an average price of NOK 114.00 per share. Following this transaction, Tone Kvåle and related parties will together own 179,608 shares in Nordic Nanovector ASA and Tone Kvåle holds 210,000 options in the company.

On 8 December 2016, Lisa Rojkjaer, Chief medical officer of Nordic Nanovector ASA purchased 2,186 shares in Nordic Nanovector ASA at an average price of NOK 114.00 per share. Following this transaction, Lisa Rojkjaer owns 2,186 shares in Nordic Nanovector ASA and holds 340,000 options in the company.

On 8 December 2016, Anniken Hagen, Chief technical and operations officer of Nordic Nanovector ASA purchased 1,754 shares in Nordic Nanovector ASA at an average price of NOK 114.00 per share. Following this transaction, Anniken Hagen owns 63,858 shares in Nordic Nanovector ASA and holds 142,000 options in the company.

On 8 December 2016, Rita Dege, Chief human resources officer of Nordic Nanovector ASA purchased 1,754 shares in Nordic Nanovector ASA at an average price of NOK 114.00 per share. Following this transaction, Rita Dege owns 4,754 shares in Nordic Nanovector ASA and holds 32,000 options in the company.

This information is subject to duty of disclosure pursuant to Section 4-2 of the Norwegian Securities Trading Act.

   


Tags:

About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at www.nordicnanovector.com

Subscribe